REG - Futura Medical PLC - Capital Markets Event <Origin Href="QuoteRef">FUM.L</Origin>

Futura MedicalAnnouncement

26/01/2016 07:00

RNS Number : 9287M
Futura Medical PLC
26 January 2016
For immediate release 
26 January 2016
Futura Medical plc
("Futura" or the "Company")
Capital Markets Event
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will this afternoon host a capital markets event for equity analysts and institutional investors. 
The event will be webcast. To access the webcast live, please log on to the following web address approximately 5 minutes before 3.15pm GMT today:
http://vm.buchanan.uk.com/2016/futuramedical260116/registration.htm
A recording of the webcast will be made available for several days from 27 January 2016 at www.futuramedical.com and at www.buchanan.uk.com.
The capital markets event will provide details of progress across the Company's portfolio of products. On CSD500, Futura's erectogenic condom, attendees of the event will be informed that the Company continues to receive positive stability data from its modified manufacturing process. This data indicates an extended shelf life for the product in line with distributors' requirements.
The presentations on MED2002, Futura's novel gel for erectile dysfunction, will include an update on recruitment to the current pivotal clinical study, which now has a total of 171 patients enrolled in the run-in phase of the study. The announcement of headline data from the study remains on track for the end of H1 2016.
Presentations on the Company's topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen), will include an overview of the potential regulatory pathway for the products, which remains in line with previous announcements, as well as an outline of the likely commercialisation strategy. 
Analysts and investors who would like to attend the capital markets event, please contact Buchanan at the details below.
For further information please contact:
Futura Medical plc

James Barder, Chief Executive
Tel: +44 (0) 1483 685 670
Email to: james.barder@futuramedical.com
www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz Yong / Tom Smale
Corporate Finance 
Tel:+44 (0) 20 7496 3000
For media enquiries please contact: 

Buchanan 

Mark Court / Sophie Cowles / Stephanie Watson
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEAKFSALSKEFF